MedPath

Comparing the efficacy of surfactant administration by laryngeal mask airway (LMA) and endotracheal intubatio

Phase 2
Conditions
Respiratory Distress Syndrome.
Respiratory distress syndrome
Registration Number
IRCT201411183915N12
Lead Sponsor
Research Vice Chancellor for Tabriz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
70
Inclusion Criteria

gestation age 33-37 weeks; confirmed diagnosis of respiratory distress syndrome according to clinical and radiological findings; treatment with surfactant
Exclusion criteria: major congenital anomalies; congenital heart disease; cranio-facial anomalies; esophageal atresia; birth weight less than 1800 grams

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduced needed FiO2 to maintain adequate oxygenation. Timepoint: Before and one hour after surfactant therapy. Method of measurement: Determination of needed Fio2 in blender and by pulse oxymetry.
Secondary Outcome Measures
NameTimeMethod
eed for intubation and assisted ventilation. Timepoint: Till 3 days after treatment. Method of measurement: Pulse oxymetry and blood gas analysis.
© Copyright 2025. All Rights Reserved by MedPath